Quest Diagnostics (DGX) 10-K Summaries & Annual Filing History
Review Quest Diagnostics Incorporated (DGX) 10-K filings from 2023 through the latest annual report, including business, financial performance, risks, and liquidity.
Key takeaway
Year ended Dec 31, 2025 · FY2025 10-K
Quest Diagnostics reported revenue growth and improved operating cash flow for the period. The company's liquidity position decreased slightly as it used cash for investing and financing activities.
Financial snapshot
Selected annual figures reported with the filing, shown separately from the narrative summary.
Annual revenue
$11B
Revenue reported for the fiscal year.
Operating income
$1.6B
Income from operations reported for the year.
Net income
$992M
Net income reported for the year.
Operating cash flow
$1.9B
Cash generated by operating activities.
Annual revenue trend
Reported annual revenue and its change from the preceding fiscal year.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Dec 31, 2022 | $9.9B | -8.4% |
| Dec 31, 2023 | $9.3B | -6.4% |
| Dec 31, 2024 | $9.9B | +6.7% |
| Dec 31, 2025 | $11B | +11.8% |
Business overview
The company operates in the clinical testing industry, as described in its Business overview section. The filing covers strategy, strengths, operations, and regulation.
Financial performance
Revenue increased compared to the prior period, while operating income and net income were reported at positive levels. Net cash provided by operating activities improved significantly.
Material risks
The filing includes risk factors related to the company's operations, regulatory environment, and future results, as outlined in Item 1A.
Liquidity and capital
The company generated strong operating cash flow, which was used for investing and financing activities, resulting in a net decrease in cash and cash equivalents.
What to watch
Investors should monitor the impact of the OBBBA and CARES Act payroll tax credit on future cash flows, as these items affected the current period's tax payments.